The CH50 test asks a functional question: can the proteins in the classical complement pathway work together to complete a full immune reaction? In lupus, the answer may be reduced because complement proteins are being activated and consumed by immune complexes. But a low CH50 is not specific to lupus, and it does not automatically mean a flare is occurring.
CH50 is different from measuring the concentration of one complement protein such as C3 or C4. It evaluates the combined activity of the classical pathway through the terminal pathway. A very low result can reflect active immune-complex disease, an inherited missing complement component, severe liver disease, a complement-blocking medication, or a sample that was not handled correctly. Interpretation is therefore strongest when CH50 is reviewed with C3, C4, anti-double-stranded DNA antibodies, symptoms, urinalysis, kidney function, blood counts, and prior results.
- CH50 measures total functional activity of the classical complement pathway, not one protein level.
- In lupus, a falling or low CH50 may reflect complement consumption, but it is not a stand-alone flare test.
- A near-zero CH50 can suggest a complement deficiency, medication effect, or preanalytical problem.
- CH50 and AH50 together help localize which complement pathway may be impaired.
- Trends are most useful when compared with a person’s own baseline and objective organ findings.
Table of Contents
- What CH50 actually tests
- Why CH50 is used in lupus
- Causes of a low CH50
- CH50, C3, C4, and AH50 together
- Sample handling and assay limitations
- How results affect next steps
- Questions to ask about your result
What CH50 actually tests
Complement is a network of circulating proteins that helps antibodies clear microbes and damaged material, recruits inflammatory cells, and can form a membrane attack complex that damages target-cell membranes. It can be activated through three main routes: the classical, lectin, and alternative pathways. These routes converge at C3 and then share the terminal components C5 through C9.
CH50 is commonly expanded as total hemolytic complement or 50% hemolytic complement activity. In the traditional assay, a patient’s serum is mixed with antibody-coated sheep red blood cells. The laboratory determines how effectively the serum lyses the cells. Modern laboratories may use modified hemolytic or enzyme-based functional methods, but the principle remains the same: every required component in the classical and terminal pathways must be sufficiently active for the reaction to reach completion.
The test depends on functioning C1, C2, C4, C3, and C5 through C9. If one essential component is absent or severely depleted, the pathway may fail and CH50 can become extremely low or undetectable. This “weakest link” property makes CH50 useful as a screening test for functional complement defects.
CH50 is not the same as:
- A C3 test, which measures the amount of complement component C3.
- A C4 test, which measures the amount of complement component C4.
- AH50, which evaluates alternative-pathway function.
- Complement split products such as C3a, C4d, or soluble C5b-9, which reflect activation products and are used mainly in specialized or evolving clinical contexts.
A normal concentration of an individual protein does not guarantee that the whole pathway functions normally. Conversely, a mildly low C3 or C4 does not always drive CH50 below the reference interval. The tests answer related but different questions.
Reference ranges vary substantially by method and laboratory. Results may be reported in units per milliliter, percent activity, or another assay-specific format. A value should be compared only with the reference interval on that report and, for trends, ideally with results from the same method.
Why CH50 is used in lupus
Systemic lupus erythematosus can generate antibodies that bind nuclear material and form immune complexes. When these complexes activate the classical complement pathway, complement components are consumed faster than they are replaced. This can lower C3, C4, and CH50.
For that reason, complement testing is often included in a lupus blood test panel. It may be ordered during diagnosis, routine monitoring, investigation of new symptoms, or assessment of suspected lupus nephritis.
CH50 can contribute in several ways:
Supporting an immune-complex pattern
A low CH50 together with low C3 and C4 may support active classical-pathway consumption. In a patient with compatible symptoms, positive lupus serology, and objective inflammation, that pattern adds evidence that immune-complex activity is occurring.
Low complement is included in modern lupus classification frameworks, although commonly used criteria specifically score low C3 and/or C4 rather than CH50. Classification criteria are tools for research consistency and do not replace diagnosis by a clinician.
Following a personal trend
Some patients have a characteristic complement pattern during active disease. CH50 may fall before or during a flare and recover with treatment. For those individuals, serial results can add useful context. The person’s established baseline often matters more than whether a value is one unit outside a population reference range.
Evaluating possible kidney involvement
Lupus nephritis can be accompanied by low complement, rising anti-double-stranded DNA antibodies, protein or blood in urine, and changes in kidney function. CH50 may support the overall picture, but urinalysis, urine protein quantification, creatinine, blood pressure, and sometimes kidney biopsy are more direct measures of renal involvement.
Investigating unexpectedly persistent hypocomplementemia
If CH50 remains profoundly low when lupus appears clinically quiet, clinicians may consider inherited complement deficiency, chronic consumption from another condition, assay interference, medication effect, or sample-handling problems. Early classical-component deficiencies can themselves increase susceptibility to lupus-like autoimmunity, so deficiency and lupus are not mutually exclusive explanations.
CH50 also has limitations as a lupus biomarker. Some patients flare with normal complement. Others remain low even when clinically stable. Complement proteins are acute-phase reactants, so increased production during inflammation can partly mask consumption. Treatment decisions should never be based on CH50 alone.
Causes of a low CH50
“Low CH50” describes a laboratory finding, not a diagnosis. The pattern and degree of reduction help narrow the possibilities.
Active complement consumption
Immune-complex diseases can activate and consume classical-pathway components. Lupus is a major example, particularly when kidneys, blood vessels, skin, joints, or other organs are actively inflamed. Cryoglobulinemia, some forms of glomerulonephritis, endocarditis, and other immune-complex conditions can produce a similar pattern.
Consumption often lowers C3 and C4 as well, but not always to the same degree. C4 may fall prominently with classical-pathway activation, while C3 can be affected by several pathways. The clinical setting determines which explanation is most likely.
Inherited complement deficiency
Genetic absence or severe dysfunction of a classical-pathway component can make CH50 nearly zero. Deficiencies of C1q, C1r, C1s, C2, or C4 are associated with increased risk of lupus or lupus-like disease because early complement helps clear apoptotic material and immune complexes. Terminal-component deficiencies involving C5 through C9 are especially associated with recurrent invasive Neisseria infections.
Clues to an inherited deficiency include:
- CH50 that is repeatedly undetectable rather than merely modestly low.
- Recurrent meningococcal or other unusual bacterial infections.
- Autoimmune disease beginning at a young age.
- A family history of similar infection or autoimmune patterns.
- A result that remains extremely low during clinically quiet disease.
Confirmatory work may include AH50, individual component levels or function, and genetic testing.
Reduced production
Many complement proteins are synthesized in the liver. Severe liver dysfunction can reduce production and lower functional activity. Malnutrition or substantial protein loss may contribute in some settings. These causes are assessed with the full medical history and liver, kidney, and nutritional data.
Complement-targeted therapy
Drugs that intentionally block complement can suppress functional assays. C5 inhibitors such as eculizumab or ravulizumab typically make terminal pathway activity very low, affecting CH50 and often AH50. Other complement-directed agents may create different patterns depending on their target. In this context, a low result may demonstrate expected pharmacologic effect rather than a lupus flare.
Medication history is essential because complement inhibitors are used for conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and other complement-mediated diseases.
Preanalytical loss of activity
Complement proteins are labile. Delayed separation, storage at an unsuitable temperature, repeated freeze-thaw cycles, or transport problems can activate or degrade complement after the blood draw. The result may be falsely low. When the value is unexpected or inconsistent with C3, C4, and the clinical picture, repeating the test with careful handling may be appropriate.
CH50, C3, C4, and AH50 together
The combination of functional and concentration tests is more informative than any one result. The table below shows common screening patterns; it is a guide, not a substitute for specialist interpretation.
| CH50 | AH50 | Possible interpretation |
|---|---|---|
| Low | Normal | Classical-pathway defect or consumption affecting components unique to that pathway, such as C1, C2, or C4 |
| Normal | Low | Alternative-pathway defect involving factors such as factor B, factor D, or properdin |
| Low | Low | Defect or major depletion in the shared terminal pathway, C3 deficiency, broad consumption, severe production failure, complement blockade, or poor specimen integrity |
| Normal | Normal | Major functional deficiency of the tested pathways is unlikely, though lectin-pathway defects and partial abnormalities can still be present |
C3 and C4 refine the pattern:
- Low CH50, low C3, and low C4 can fit active classical-pathway consumption in lupus.
- Low CH50 with very low C4 and relatively preserved C3 may occur with prominent classical-pathway activation or an early-component problem.
- Undetectable CH50 with normal measured C3 and C4 raises concern for another missing classical or terminal component, a functional defect, medication effect, or specimen problem.
- Low C3 with normal C4 can suggest alternative-pathway activation, although clinical overlap exists.
- Persistently low C4 with stable CH50 and no activity may reflect genetically lower C4 copy number in some people.
The word “normal” also needs nuance. A result can stay inside a population reference range while dropping substantially from a person’s usual level. Conversely, a chronically low baseline may not signal new activity. Clinicians should look at direction, magnitude, timing, and the rest of the disease data.
A high CH50 is generally less diagnostically specific. Complement proteins can rise as acute-phase reactants during inflammation, infection, or other states. An elevated value does not mean the immune system is “too strong,” and it is rarely used by itself to diagnose a particular disorder.
Sample handling and assay limitations
Functional complement assays are unusually sensitive to what happens before analysis. This is one reason a surprising result should be verified before it drives a major diagnosis.
The laboratory may require serum to be separated promptly and frozen if analysis is delayed. Exact requirements differ, so collection sites should follow the performing laboratory’s instructions. A sample left at room temperature too long can lose activity. Plasma collected in the wrong tube may also be unsuitable for some methods.
Other limitations include:
- Method differences: Traditional hemolytic assays and newer liposome or enzyme-based methods may have different units and performance characteristics.
- Upper and lower reporting limits: A report may say “less than” a threshold rather than provide an exact value. Near-zero results are clinically different from mild reductions.
- Biologic variability: Complement changes with infection, inflammation, pregnancy, liver synthesis, protein loss, and therapy.
- Partial deficiencies: A person with reduced but not absent component activity may have a CH50 within or near the reference interval.
- Balance of consumption and production: Active inflammation can increase liver production while immune activation consumes complement, producing an apparently normal concentration.
- Lack of organ specificity: CH50 cannot tell whether the kidneys, skin, joints, blood, brain, or another site is affected.
Complement activation products and cell-bound complement markers are being studied and used in selected settings because they may capture activation more directly than static C3 or C4 levels. They have not replaced conventional testing across routine lupus care, and availability and standardization vary.
A clinician should be cautious when a lone CH50 result conflicts with every other finding. Repeat collection, assay review, and targeted component testing are often more useful than assuming the disease has abruptly changed.
How results affect next steps
In a person with known or suspected lupus, the response to a low CH50 depends on symptoms and associated tests.
When a flare is possible, clinicians may check:
- C3 and C4.
- Anti-dsDNA or other relevant serology.
- Complete blood count.
- Creatinine and estimated filtration rate.
- Urinalysis, urine sediment, and urine protein-to-creatinine ratio.
- Liver tests and markers of inflammation.
- Blood pressure and a focused organ examination.
New proteinuria, blood or cellular casts in urine, rising creatinine, marked blood-count changes, serositis, neurologic symptoms, vasculitic lesions, or other objective findings may require urgent assessment. A kidney biopsy may be needed to classify suspected lupus nephritis and guide therapy; CH50 cannot replace it.
When inherited deficiency is possible, immunology evaluation may include repeat CH50, AH50, individual complement components, functional assays, and genetic testing. Confirmed terminal-component deficiency can affect vaccination, antibiotic planning, and education about meningococcal symptoms. Family testing may be discussed.
When a complement inhibitor is being used, clinicians interpret CH50 according to the drug target and monitoring protocol. Suppressed activity may be expected. The patient should not stop or alter treatment based on a laboratory result without the prescribing specialist.
A mildly low CH50 in a clinically stable patient may lead only to repeat testing and observation. The goal is to react to the whole pattern, not to normalize every laboratory number.
Questions to ask about your result
Useful questions include:
- Was my CH50 mildly low or essentially undetectable?
- Were C3 and C4 low at the same time?
- How does this compare with my prior baseline?
- Do my symptoms, urine tests, kidney function, or blood counts suggest active lupus?
- Could the sample have been delayed, warmed, or otherwise mishandled?
- Am I taking a medication that intentionally blocks complement?
- Should AH50 or individual complement components be tested?
- Does my infection history raise concern for an inherited deficiency?
- Which findings would change treatment, and which will simply be watched?
Bring prior results if testing was performed in another health system. A graph of CH50, C3, C4, anti-dsDNA, urine protein, and creatinine over time can reveal whether the laboratory pattern reliably tracks your disease.
The central lesson is that CH50 is a pathway-function test. In lupus, it can strengthen evidence for complement consumption and add value to longitudinal monitoring. Its meaning becomes clear only after clinicians distinguish active immune use from inherited absence, reduced production, medication blockade, and specimen-related loss of activity.
References
- Complement as a Biomarker for Systemic Lupus Erythematosus (2023, PubMed Central)
- Pitfalls in Complement Analysis: A Systematic Literature Review of Assessing Complement Activation (2022, PubMed Central)
- The Complement System and Human Autoimmune Diseases (2022, PubMed Central)
- EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update (2024, PubMed)
- Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both? (2021, PubMed Central)
- Complement Deficiency and Anticomplement Therapeutic Response Monitoring (2025, ARUP Consult)
Disclaimer
This article is educational and does not diagnose a lupus flare or complement deficiency. CH50 must be interpreted by a qualified clinician with C3, C4, medication history, specimen details, symptoms, and organ-specific tests. Seek urgent care for severe infection symptoms, chest pain, major breathing difficulty, neurologic changes, or signs of acute kidney disease.
